Rxsight Inc
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | -683.6% | – | – | – | – | – | – | – | |
| – | -4.1% | +5.2% | -28.1% | +39.1% | -54.2% | +50.1% | -1.1% | +10.1% | -0.4% | -2.0% | +19.8% | – | |
| – | +8.7% | +6.1% | +30.0% | +7.3% | +11.1% | -2.0% | +19.7% | -5.1% | -3.6% | +1.6% | -6.0% | – | |
| – | – | – | – | – | -291.3% | – | – | – | -66.5% | -441.1% | – | – | |
| – | +143.6% | +23.6% | -22.6% | -27.6% | -23.2% | -32.1% | +167.3% | -62.2% | +95.7% | -33.2% | +157.7% | – | |
| – | -73.6% | +431.6% | -576.4% | -92.0% | – | +1,479.9% | -29.7% | -161.5% | +6.8% | – | -47.4% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -99.8% | +106,600.0% | – | +213,200.0% | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | +9.1% | +8.3% | -76.9% | +533.3% | – | -177.8% | +0.0% | – | |
| – | – | +55.2% | +1,295.8% | -99.3% | +272.9% | -124.7% | – | -125.7% | – | -131.6% | – | – | |
| – | -115.8% | – | -135.7% | – | – | – | +9.4% | -186.8% | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.